PTC Therapeutics (PTCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Four Class I directors nominated for election: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on named executive officer compensation (say-on-pay) included.
Provision to transact other business as may be properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Executive compensation and say-on-pay
Advisory vote solicited on executive compensation as described in the proxy statement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PTC Therapeutics
- Sephience’s global launch and pipeline progress drive strong growth and future outlook.PTCT
Corporate presentation11 May 2026 - Sephience's launch drove 47% revenue growth and a raised 2026 outlook, despite a net loss.PTCT
Q1 20268 May 2026 - Votoplam slowed Huntington's disease progression by up to 52% at 24 months with sustained safety.PTCT
Study result28 Apr 2026 - 2026 meeting covers director elections, auditor ratification, and performance-based executive pay.PTCT
Proxy filing20 Apr 2026 - 2025 revenue and net income surged on Sephience uptake and Novartis deal; 2026 growth expected.PTCT
Q4 202512 Apr 2026 - Sephience drives robust growth and pipeline expansion, with strong launch momentum and broad R&D progress.PTCT
Leerink Global Healthcare Conference 202624 Mar 2026 - Sepiapterin’s rapid global launch drives strong PKU adoption and robust pipeline momentum.PTCT
Barclays 28th Annual Global Healthcare Conference20 Mar 2026 - Sephience's launch accelerates growth, with pipeline and global expansion fueling future momentum.PTCT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Surpassed 2025 revenue targets and set ambitious 2026 growth and R&D milestones.PTCT
Corporate presentation27 Feb 2026